[<sup>18</sup>F]FDG-PET in Lung Cancer: From Staging to Therapy Response.
Authors
Singh H,Aggarwal P,Kumar R,Singh N
Affiliations (4)
Affiliations (4)
- Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Electronic address: [email protected].
- Department of Nuclear Medicine, Sri Aurobindo Institute of Medical Sciences (SAIMS), Indore, India.
- Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Abstract
Lung cancer, the most commonly diagnosed malignancy, is the leading cause of cancer-related mortality worldwide. Advancements in molecular imaging have expanded the role of [18F] 2-Fluoro-2-deoxy-glucose (FDG) PET/CT in the management of lung cancer, from the evaluation of pulmonary nodules (including solitary pulmonary nodule) to staging, radiotherapy planning and response evaluation. This review summarizes updates on the utility of FDG PET in non-small-cell lung cancer and expands on the current and future potential of artificial intelligence and radiogenomics in molecular imaging.
Topics
Journal ArticleReview